1. Home
  2. GROW vs UBX Comparison

GROW vs UBX Comparison

Compare GROW & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GROW
  • UBX
  • Stock Information
  • Founded
  • GROW 1968
  • UBX 2009
  • Country
  • GROW United States
  • UBX United States
  • Employees
  • GROW N/A
  • UBX N/A
  • Industry
  • GROW Investment Managers
  • UBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GROW Finance
  • UBX Health Care
  • Exchange
  • GROW Nasdaq
  • UBX Nasdaq
  • Market Cap
  • GROW 32.9M
  • UBX 38.6M
  • IPO Year
  • GROW N/A
  • UBX 2018
  • Fundamental
  • Price
  • GROW $2.44
  • UBX $2.19
  • Analyst Decision
  • GROW
  • UBX Strong Buy
  • Analyst Count
  • GROW 0
  • UBX 2
  • Target Price
  • GROW N/A
  • UBX $7.00
  • AVG Volume (30 Days)
  • GROW 27.6K
  • UBX 333.6K
  • Earning Date
  • GROW 02-12-2025
  • UBX 11-04-2024
  • Dividend Yield
  • GROW 3.69%
  • UBX N/A
  • EPS Growth
  • GROW N/A
  • UBX N/A
  • EPS
  • GROW 0.04
  • UBX N/A
  • Revenue
  • GROW $9,421,000.00
  • UBX N/A
  • Revenue This Year
  • GROW N/A
  • UBX N/A
  • Revenue Next Year
  • GROW N/A
  • UBX $33.62
  • P/E Ratio
  • GROW $66.14
  • UBX N/A
  • Revenue Growth
  • GROW N/A
  • UBX N/A
  • 52 Week Low
  • GROW $2.38
  • UBX $0.94
  • 52 Week High
  • GROW $2.95
  • UBX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • GROW 48.78
  • UBX 58.41
  • Support Level
  • GROW $2.43
  • UBX $1.81
  • Resistance Level
  • GROW $2.49
  • UBX $2.39
  • Average True Range (ATR)
  • GROW 0.04
  • UBX 0.24
  • MACD
  • GROW -0.00
  • UBX -0.05
  • Stochastic Oscillator
  • GROW 25.00
  • UBX 59.38

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Share on Social Networks: